NeoGenomics (NASDAQ:NEO) Releases FY 2024 Earnings Guidance

NeoGenomics (NASDAQ:NEO) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.080-0.100 for the period, compared to the consensus estimate of 0.060. The company issued revenue guidance of $655.0 million-$667.0 million, compared to the consensus revenue estimate of $661.7 million.

NeoGenomics Stock Up 2.3 %

Shares of NeoGenomics stock traded up $0.36 on Thursday, reaching $15.82. The stock had a trading volume of 940,050 shares, compared to its average volume of 820,345. The company has a 50 day moving average price of $14.69 and a 200 day moving average price of $14.73. The company has a quick ratio of 1.93, a current ratio of 2.01 and a debt-to-equity ratio of 0.37. NeoGenomics has a 1 year low of $12.77 and a 1 year high of $21.22. The stock has a market capitalization of $2.03 billion, a P/E ratio of -25.52 and a beta of 1.19.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04. The company had revenue of $167.80 million during the quarter, compared to analysts’ expectations of $167.00 million. NeoGenomics had a negative net margin of 12.50% and a negative return on equity of 2.72%. NeoGenomics’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period last year, the business earned ($0.06) EPS. As a group, equities research analysts forecast that NeoGenomics will post -0.21 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on NEO shares. Benchmark reissued a “buy” rating and issued a $18.00 price target on shares of NeoGenomics in a report on Tuesday, September 24th. Stephens reaffirmed an “overweight” rating and set a $19.00 target price on shares of NeoGenomics in a report on Tuesday, July 30th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a report on Wednesday. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.89.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.